Dr Mathew Smith

2024

• Rawlings, A. et al., 2024. The burden of acute eye conditions on different healthcare providers: a retrospective population-based study. British Journal of General Practice 74 , pp.e264-e274. (10.3399/BJGP.2022.0616)

2021

• Orayj, K. et al. 2021. Factors affecting the choice of first-line therapy in Parkinson's disease patients in Wales: A population-based study. Saudi Pharmaceutical Journal 29 (2), pp.206-212. (10.1016/j.jsps.2021.01.004)

2019

• Orayj, K. et al. 2019. Association between levodopa and ischemic heart disease. International Journal of Population Data Science 4 (3) 011. (10.23889/ijpds.v4i3.1172)

2017

• De Vis, P. et al., 2017. Herschel-ATLAS: revealing dust build-up and decline across gas, dust and stellar mass selected samples – I. Scaling relations. Monthly Notices of the Royal Astronomical Society 464 (4), pp.4680-4705. (10.1093/mnras/stw2501)
• Johnson, I. et al. 2017. Learning how "professions can work together to provide the best care": Dental-pharmacy inter-professional education presenter. Presented at: Learning together to improve oral health and quality of life Vilnius, Lithuania 23-26 August 2017. , pp.45-45.

2016

• Jenkins, A. I. et al. 2016. Too far away to work with each other: Does location impact on pharmacists' perceptions of interprofessional interactions?. Journal of Interprofessional Care 30 (5), pp.678-681. (10.1080/13561820.2016.1191451)

2015

• Aljayyoussi, G. et al., 2015. Absorption of ipratropium and L-carnitine into the pulmonary circulation of the ex-vivo rat lung is driven by passive processes rather than active uptake by OCT/OCTN transporters. International Journal of Pharmaceutics 496 (2), pp.834-841. (10.1016/j.ijpharm.2015.10.036)

2013

• Aljayyoussi, G. et al. 2013. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: A study in ex vivo lung models using chemical inhibition and genetic knockout. Journal of Pharmaceutical Sciences 102 (9), pp.3382-3394. (10.1002/jps.23587)
• Campbell, L. et al. 2013. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease. Journal of Translational Medicine 11 (1) 255. (10.1186/1479-5876-11-255)

2012

• Smith, M. W. , Aljayyoussi, G. and Gumbleton, M. 2012. Peptide sequences mediating tropism to intact blood-brain barrier: An in vivo biodistribution study using phage display. Peptides 38 (1), pp.172-180. (10.1016/j.peptides.2012.06.019)

2011

• Gumbleton, M. et al. 2011. Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Advanced Drug Delivery Reviews 63 (1-2), pp.110-118. (10.1016/j.addr.2010.09.008)
• Morris, C. J. et al. 2011. Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. Journal of Controlled Release 151 (1), pp.83-94. (10.1016/j.jconrel.2010.12.003)
• Smith, M. W. , Birchall, J. C. and Coulman, S. 2011. The wider contribution of microbiology to the pharmaceutical sciences. In: Denver, S. P. et al., Hugo and Russell's Pharmaceutical Microbiology 8th Edition. Wiley-Blackwell. , pp.463-482.

2009

• Smith, M. W. 2009. Phage display and experimental brain therapeutics. PhD Thesis , Cardiff University.

2007

• Barar, J. et al., 2007. Cell selective glucocorticoid induction of caveolin-1 and caveolae in differentiating pulmonary alveolar epithelial cell cultures. Biochemical and Biophysical Research Communications 359 (2), pp.360-366. (10.1016/j.bbrc.2007.05.106)
• Smith, M. W. , Omidi, Y. and Gumbleton, M. 2007. Primary porcine brain microvascular endothelial cells: Biochemical and functional characterisation as a model for drug transport and targeting. Journal of Drug Targeting 15 (4), pp.253-268. (10.1080/10611860701288539)

2006

• Smith, M. W. and Gumbleton, M. 2006. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. Journal of Drug Targeting 14 (4), pp.191-214. (10.1080/10611860600650086)